Our collaboration with SPH Kyuan Trade represents a pivotal moment in Orphalan's journey. We are not just bringing a treatment to market; we are revolutionizing access to care for those who need ...

It has taken French rare disease specialist Orphalan 11 years to earn its first approval in the U.S. But that’s nothing compared to how long people with Wilson’s disease have waited for a new ...

Paris, France 1 February2022 - Orphalan SA, a Company that identifies, develops, and delivers therapies worldwide for orphan diseases, today announces two new appointments to the management team.

MIAMI, May 4, 2022 /PRNewswire/ -- Brand Institute is proud to announce working with rare disease specialist, Orphalan, in developing the brand name CUVRIOR™, approved by the United States Food ...

Paris, France [26 July], 2022 -- Orphalan SA (“Orphalan” or “the Company”), an international orphan drug development and commercialization company, today announces the enrolment of the ...

Paris, France, April 20, 2023 – Orphalan SA (“Orphalan” or “the Company”), an international orphan drug development and commercialization company, today announces the commercial launch i ...

in China. This landmark achievement makes Orphalan the first European pharmaceutical company to introduce an orphan drug to the Chinese Wilson Disease market marking a significant step forward in ...